Skip to main content
. Author manuscript; available in PMC: 2024 Apr 1.
Published in final edited form as: Obstet Gynecol. 2023 Mar 9;141(4):845–853. doi: 10.1097/AOG.0000000000005117

Figure 3:

Figure 3:

Comparison of medication for opioid use disorder discontinuation among pregnant (red) versus nonpregnant (blue) reproductive-aged women with opioid use disorder. A. Buprenorphine. Length of treatment (days) (χ2=59.89; degrees of freedom=1; P<.001). B. Methadone. Length of treatment (days) (χ2=46.59; degrees of freedom=1; P<.001).